Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Non-Hodgkin 6Recurrence 4Lymphoma 4Leukemia 4Lymphoma, Follicular 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Prolymphocytic, T-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

venetoclax 1obinutuzumab 1liposomal doxorubicin 1duvelisib 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1CA-4948 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × duvelisib × Other hematologic neoplasm × Clear all
NCT02292225 2023-02-27

Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)

SecuraBio

Phase 1 Terminated
3 enrolled
LymphoidOther hematologic neoplasm

Hereditary Sensory and Autonomic Neuropathies, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡